{
    "clinical_study": {
        "@rank": "75432", 
        "arm_group": [
            {
                "arm_group_label": "Group 1-5, single ascending dose AZD7624", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a First in Human study to assess the safety and tolerability of AZD7624, following\n      inhaled administration  of single ascending doses in healthy male volunteers and female\n      volunteers of non-child bearing potential.  Pharmacokinetics (what the body does to the\n      drug) and pharmacodynamic (what the drug does to the body) parameters will be also assessed\n      as secondary objectives."
        }, 
        "brief_title": "A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Double-blind Placebo-controlled, Randomised, Single centre, First Time in Man Study to\n      evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending\n      Inhaled Doses of AZD7624 in Healthy Subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects aged 18 to 55 years\n\n          -  Able to inhale from the SPIRA nebuliser according to the provided instructions\n\n          -  Females must have a negative pregnancy test at screening and on admission (Day  1) to\n             the CPU, must not be lactating and must be of non-childbearing potential.\n\n          -  Body mass index (BMI) between 18 and 30 kg/m2 inclusive and weighing at least 50 kg\n             and no more than 100 kg inclusive.\n\n          -  FEV1 >80% of the predicted normal value.\n\n        Exclusion Criteria:\n\n          -  History of severe allergy/hypersensitivity or ongoing clinically important\n             allergy/hypersensitivity, as judged by the Investigator or history of\n             hypersensitivity to drugs with a similar chemical structure or class to AZD7624\n\n          -  History of any clinically important disease or disorder which, in the opinion of the\n             Investigator, may either put the subject at risk because of participation in the\n             study, or influence the results or the subject's ability to participate in the study\n\n          -  History or family history of muscle diseases\n\n          -  Known or suspected history of drug abuse as judged by the Investigator\n\n          -  Use of any prescribed or non-prescribed medication including antacids, analgesics\n             other than paracetamol/acetaminophen, herbal remedies, vitamins (excluding routine\n             vitamins but including megadose [intake of 20 to 600 times the recommended daily\n             dose])"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754844", 
            "org_study_id": "D2550C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1-5, single ascending dose AZD7624", 
                "description": "Single dose inhaled IMP via a nebulizer", 
                "intervention_name": "AZD7624", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single dose inhaled Placebo via a nebulizer", 
                "intervention_name": "Placebo to match", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase 1", 
            "Healthy Volunteers", 
            "Single Ascending Dose (SAD)", 
            "First Time in Man", 
            "Pharmacokinetics", 
            "Pharmacodynamics"
        ], 
        "lastchanged_date": "September 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind Placebo-controlled, Randomised, Single Centre, First Time in Man Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD7624 in Healthy Subjects", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca Research and Development     SE-431 83 Molndal Sweden", 
                "last_name": "Sam Lindgren, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Quintiles Drug Research Unit at Guy's Hospital 6 Newcomen St London SE1 1YR", 
                "last_name": "Darren G Wilbraham", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety variables (adverse events, vital signs, body temperature, ECGs, clinical laboratory safety tests and spirometry)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 55 days."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754844"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics of AZD7624 and assess dose proportionality of the pharmacokinetics following single ascending doses of AZD7624 by assessment of Cmax, t1/2, AUC and CL/F.", 
                "safety_issue": "No", 
                "time_frame": "Day 1 pre-dose, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 9h,12h, 18h, 24h, 36h, 48h, 56h post dose"
            }, 
            {
                "measure": "Pharmacokinetics of single doses of AZD7624 using the following urine PK parameters: Ae and CLR", 
                "safety_issue": "No", 
                "time_frame": "Day 1: during 0-6, 6-12, 12-24 and 24-48 hours post dose."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}